Strengthening and Extension of the Industrial Protection of Livatag® until 2031
20-Feb-2014
|
Source :
|
Visits : 6511
PARIS - BioAlliance Pharma SA (Euronext Paris – BIO), an innovative company dedicated to the development of orphan oncology products, announced in a press release a major strengthening of the patent protection for its product Livatag® (doxorubicine Trandrug™), currently in phase III clinical trial in primary liver cancer (ReLive trial).
The European Patent Office has issued a new patent family for Livatag® protecting its specific administration scheme. This first delivery should be followed by many others since the patent application is under review in about twenty other territories worldwide (including the United States, Asia and Latin America).
Livatag® was already patented until 2019 on an international level with a first patent family protecting its composition (doxorubicin encapsulated in nanoparticles). It also benefits from a commercial exclusivity linked to its orphan status in Europe and in the United States, which covers from 7 to 10 years from the market authorization.
This second patent family significantly strengthens and extends Livatag®’s protection as it expands it until 2031, until which period no generic may be commercialized.
"This new patent has not only reinforced but has also strongly extended the protection of Livatag®. This represents a significant additional potential of revenues for such a product whose estimated level of sales could reach up 800 million Euros,” commented Judith Greciet, CEO of BioAlliance Pharma.
"We are very pleased with the delivery of this new patent for Livatag®, the fruit of a very close collaboration between the Company’s Development and Industrial Property teams. These constant interactions allow us to ensure an optimal patent protection to our programs, thereby maximizing permanently their valorization,” added Aude Michel, Head of Corporate Development at BioAlliance Pharma.